Quince Therapeutics Financials - Benzinga

Quince Therapeutics Inc

QNCXNASDAQ

Trade with Public

Trade with Public

$30.15

-1.20-3.83%

近くで: Sep 23, 5:00 PM EST

$27.92

-2.23-7.4%

時間外: Sep 14, 7:40 AM EST

概要ニュース業績予想イベント目標株価財務センチメント株主構成比較オプション株式レポート

Quince Therapeutics Financials

Quince Therapeutics (QNCX) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Quince Therapeutics Q2 EPS $(12.31) Beats $(26.32) Estimate

Quince Therapeutics (NASDAQ:QNCX) reported quarterly losses of $(12.31) per share which beat the analyst consensus estimate of $(26.32) by 53.21 percent. This is a 81.9 percent increase over losses of $(68.00) per share

Benzinga Newsdesk

Gold Moves Lower; CVS Health Earnings Top Views

Avi Kapoor

PRO
Quince Therapeutics Q3 EPS $(0.25) Misses $(0.21) Estimate

Benzinga Newsdesk

PRO
Quince Therapeutics Q2 EPS $(0.34) Misses $(0.26) Estimate

Quince Therapeutics (NASDAQ:QNCX) reported quarterly losses of $(0.34) per share which missed the analyst consensus estimate of $(0.26) by 30.77 percent. This is a 46.88 percent increase over losses of $(0.64) per share

Benzinga Newsdesk

PRO
Quince Therapeutics Q3 EPS $(0.13) Up From $(0.15) YoY

Quince Therapeutics (NASDAQ:QNCX) reported quarterly losses of $(0.13) per share. This is a 13.33 percent increase over losses of $(0.15) per share from the same period last year.

Benzinga Newsdesk

PRO
Quince Therapeutics Q2 EPS $(0.64) Down From $(0.14) YoY

Quince Therapeutics (NASDAQ: QNCX) reported quarterly losses of $(0.64) per share. This is a 357.14 percent decrease over losses of $(0.14) per share from the same period last year.

Benzinga Newsdesk

© 2026 Benzinga | All Rights Reserved